Obesity paradox in patients with cancer: A systematic review and meta-analysis of 6,320,365 patients

Fausto Petrelli, Alessio Cortellini, Alice Indini, Gianluca Tomasello, Michele Ghidini, Olga Nigro, Massimiliano Salati, Lorenzo Dottorini, Alessandro Iaculli, Antonio Varricchio, Valentina Rampulla, Sandro Barni, Mary Cabiddu, Antonio Bossi, Antonio Ghidini, Alberto Zaniboni
doi: https://doi.org/10.1101/2020.04.28.20082800

Abstract

BACKGROUND Obesity, defined as a body mass index (BMI) > 30 kg/m2, is associated with a significant increase in risk of many cancers. In last years, various studies suggested that obese cancer patients have better outcomes than non-obese patients. This phenomenon, also known as “the obesity paradox”, is not well understood and presents controversial explanations. We performed a systematic review and meta-analysis to assess the association between obesity and outcome after a diagnosis of cancer.

PATIENTS AND METHODS PubMed, the Cochrane Library, and EMBASE were searched from inception to January 2020, for studies reporting prognosis of patients with obesity and cancer. Risk of death, cancer-specific survival (CSS) and progression were pooled to provide an adjusted hazard ratio with a 95% confidence interval (HR 95%CI). The primary outcome of the study refers to overall survival (OS) in obese vs non-obese patients with malignancies. Secondary endpoints were CSS and progression- or disease-free survival (PFS or RFS).

RESULTS Mortality and relapse associated with obesity in patients with cancer were evaluated among n=6,320,365 participants (n=203 studies). Overall, association of obesity and cancer was associated with a reduced OS (HR =1.14, 95% CI: 1.09-1.19; P<.01) and CSS (HR=1.17, 95%CI 1.12-1.23; P<.01). Patients were also at increased risk for relapse (HR=1.13, 95%CI 1.07-1.19; P<.01). Patients with breast, colorectal and uterine tumors were at increased risk of death. Conversely, obese with lung cancer, renal cell carcinoma and melanoma survived longer that non-obese.

CONCLUSIONS In many cancer patients, obesity reduces survival and increases the risk of relapse. In lung cancer, renal cell carcinoma and melanoma obesity was protective in terms of outcome. More intensive follow up, adequate dosing of oncological treatments, calories intake restrictions, physical activity and monitoring of obesity-related complications are effective measures for reducing mortality in these subjects.

Introduction

Obesity, defined as a body mass index (BMI) greater than 30 kg/m2, is a chronic disease with an increasing prevalence around the world, largely contributing to important health issues in most countries. Despite body fat is a general risk factor for serious illness (e.g. metabolic syndrome), greater cardiometabolic risk has also been associated with the localization of excess fat in the visceral adipose tissue and ectopic deposits1. Several large epidemiologic studies have evaluated the link between obesity and mortality. In particular, a meta-analysis of 230 cohort studies including over 30 million individuals, found that both obesity and overweight were associated with an increased risk of all-cause mortality2. Despite the evidence that excess mortality increases with increasing BMI, some studies have reached the conclusion that elevated BMI may improve survival in subjects with cardiovascular disease, a phenomenon called the “obesity paradox”3.

Increased BMI is also associated with an increased risk of multiple cancer types4. In addition, obesity and overweight may increase cancer mortality5. During last decades we also observed a more rapid increase in obesity among adult cancer survivors compared with the general population6. The mechanisms contributing to higher cancer incidence and mortality may include alterations in sex hormone metabolism, insulin and insulin-like growth factor levels, and adipokine pathways7,8.

In last years, various studies suggested that, in cancers, patients with a normal BMI have worse outcomes than obese patients. This phenomenon (the obesity paradox) in cancer, is not well understood and presents controversial explanations9,10,11. Three different metaanalyses led to different results in particular in lung and renal cell carcinomas12,13,14. In lung cancer, obesity has favourable effects on long-term survival of surgical patients. Moreover, in renal cell carcinoma an inconsistent effect of BMI on cancer-specific survival was found. Conversely, breast, ovarian and colorectal cancer are invariably associated with increased mortality in obese patients15,16,17. The main explanations proposed to answer these observations include the general poor health status of patients with very low BMI. Additionally, weight loss may usually be associated with frailty and other risk factors (e.g. smoke)10. In cancer, obesity is also associated with increased efficacy of PD-1/PD-L1 blockade in both tumor-bearing mice and patients11.

This updated systematic review and meta-analysis was conducted to evaluate the prognosis of obese vs non-obese cancer patients.

Material and methods

We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines18,19.

Search strategy and inclusion criteria

A systematic search was conducted of the EMBASE, Pubmed and The Cochrane Library published from inception until January 2020. The following search terms were used: ((carcinoma or cancer or sarcoma or melanoma or (“Neoplasms”[Mesh])) AND (obese OR obesity OR 30 kg/m2 OR “body mass index”) AND (hazard ratio) AND survival AND (multivariate OR cox). The reference lists of identified articles were then manually searched to identify potentially relevant omitted citations Articles that were not published in the English language were not included in this study.

Retrospective and observational studies (cohort, case control) or prospective trials were selected when they reported the association of obesity, defined as a BMI >30 kg/m2, with the risk of death (OS), cancer-specific death (CSS) or disease-progression (PFS or DFS) in patients with cancer. We placed no restrictions on study setting, size, race or country. The inclusion was limited to studies reporting hazard ratios (HRs) and their corresponding 95% CIs. Studies were restricted to adult patients with solid tumors. Hematologic malignancies were excluded.

The most up-to-date versions of full-text publications were included. Study selection was performed in 2 stages, first, titles and abstracts were screened; then, selected full-text articles were included according to the eligibility criteria. Screening was performed independently by 10 authors (MG, GT, AG, AI, AC, ON, VR, AI, LD, MS) and conflicts were handled by consensus with a senior author (FP).

Data Collection and quality assessment

Data were collected independently by using a predesigned spreadsheet (Excel [Microsoft]. Collected data items included authors, year of publication, study setting and design, median follow up, treatments received, outcomes, and type of analysis. The primary outcome was OS, secondary endpoints were CSS and PFS/DFS. Along with data extraction, 1 author (FP) assessed study quality according to a modified Newcastle Ottawa Scale20.

Statistical analysis

First, pooled HRs with 95% CIs were estimated using random effects meta-analysis with the generic inverse-variance method for studies that provided fully adjusted HRs. Inconsistency across studies was measured with the I2 method. Cutoff values of 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively. When I2 was larger than 50%, a random effects model was used; otherwise, the fixed effects model was used. Second, to examine heterogeneity, we performed analyses of predefined subgroups based on type of disease. Additionally, to address potential bias and verify our results, we performed sensitivity analysis using a leave-one-out method and the Trim and Fill method. Finally, to investigate the risk of publication bias, we applied the Egger test and visually inspected the funnel plots (begg’s test). All analyses were carried out using Comprehensive Meta-Analysis software,

Results

Our literature search yielded 1,892 articles, of which 203 met the inclusion criteria for our overall systematic review of the effect of obesity on cancer outcome21,22,31,121–130,32,131–140,33,141–150,34,151–160,35,161–170,36,171–180,37,181–190,38,191–200,39,201–210,40,211–220,23,41,221–223,42–50,24,51–60,25,61–70,26,71–80,27,81–90,28,91–100,29,101–110,30,111–120 (Fig. 1). Most excluded studies did not use the cut-off value for obesity (BMI values different from 30 kg/m2) or used different cut-off for risk of death (e.g. 1 kg/m2 of increase in BMI). Of the 203 articles, 170 were eligible for inclusion in the systematic review of the risk of obesity with OS, 109 for correlation with CSS, and 79 for correlation with DFS/PFS. Descriptive data for studies included in our meta-analysis are listed in Table 1. Overall, the included studies encompassed a total of 6,320,365 patients. Sample sizes ranged from 41 to 1,096,492 with a median of 1,543. Most studies were retrospective in nature (n=132), the minority were prospective cohort/observational studies (n=63) or pooled analysis/randomized trials (n=8).

Fig. 1
Fig. 1 flow diagram of included studies
View this table:
Tab. 1: characteristics of included studies

Overall survival and obesity in cancer patients

N=170 studies reported data on OS. Because the heterogeneity test showed a high level of heterogeneity (I2 =79.7%, P<.01) among studies, a random-effects model was used for the analysis. OS of obese patients was significantly worse (HR =1.14, 95% CI: 1.09-1.19; P<01; Figure 2) compared to those of not obese patients.

Figure 2
Figure 2
Figure 2
Figure 2

Cancer-specific survival and obesity in cancer patients

Similarly, obesity reduced CSS in n=109 studies (HR=1.17, 95%CI 1.12-1.23; P<.01; Figure 3), which reported data on cancer mortality. Heterogeneity was high (I2=73.9%), so a random effect model was used

Progression-free survival and obesity in cancer patients

Obese patients with cancer (n=79 studies) have a worse DFS/PFS than non-obese subjects (HR=1.13, 95%CI 1.07-1.19; P<0.01). Heterogeneity was high (I2=73.7%), so a random effect model was used.

Subgroup analysis

A subgroup analysis for OS was performed according to type of disease (Suppl. file 1), type of study (retrospective vs prospective: HR=1.07, 95%CI 1.07-1.18, P<.01 vs HR=1.14, 95%CI 1.05-1.23, P<.01), duration of follow up (> vs < 10 years HR=1.16, 95%CI 0.86-1.58, P=.08 vs HR=1.23, 95%CI 0.84–3; P=.09), race (Non asiatic HR= 1.22, 95%CI 0.86-1.6, P=.06 vs HR=1.22, 0.74-1.72, P=.09) and stage of disease (early vs advanced: HR=1.20, 95%CI 0.99-1.25, P=.072 vs HR=1.2, 95% 1.12-1.28, P=.01).

Publication bias

A funnel plot was used to assess publication bias in the studies evaluating OS in obese versus not obese cancer patients. No publication bias was detected (Begg’s test P=.23). Egger’s test was instead significant (P=0.03) (Suppl. file 2). According to the Trim and Fill method n=18 studies were placed to the left of the mean, and according the random effect model the final result was similar (HR=1.08, 95%CI 1.03-1.13). After the one study removed procedure the HR for ranged from 1.14 to 1.15.

Suppl. file 2:
Suppl. file 2:

Funnel plot of publication bias for overall survival analysis

Discussion

This meta-analysis of published (observational and retrospective) studies shows that overall mortality is increased in obese patients with breast, colorectal and uterine cancers. Cancer mortality is increased in breast, colorectal, prostate and pancreatic cancers. Finally, relapse rate is increased in breast, colorectal, prostate and gastroesophageal cancers. The “obesity paradox”, that means the apparent better cancer mortality in obese patients, is observed in lung cancer and in melanoma, despite these data derive from n=12 studies only.

Various factors are potentially linked to increased cancer mortality in some malignancies. Hormonal factors, reduced physical activity, more lethal/aggressive disease behavior, metabolic syndrome and a potential undertreatment in obese subjects are possible reasons. It is well known that postmenopausal women with higher BMI have an increased breast cancer risk due to higher estrogen levels resulting from the peripheral conversion of estrogen precursors (from adipose tissue) to estrogen224. In these patients weight loss and exercise may reduce cancer risk through lowering exposure to breast cancer biomarkers225. In colorectal cancer, BMI before diagnosis was associated with increased all-cause, cardiovascular and colorectal cancer specific mortality226. The reason of this association is presently not completely understood although insulin, insulin-like growth factors, their binding proteins, chronic inflammation, oxidative stress, and impaired immune surveillance have been supposed to be causative factors227. In pancreatic cancer higher prediagnostic BMI was associated with more advanced stage at diagnosis, with 72.5% of obese patients presenting with metastatic disease versus 59.4% of healthy-weight patients (P = .02) in 2 large prospective cohort studies222. Lastly, in prostate cancer obesity may a consequence of androgen deprivation therapy but seems also related with more aggressive disease (i.e., Gleason score ≥7)228 or more advanced disease at diagnosis229.

Our results showed that obese lung cancer patients had significantly prolonged cancer specific survival and overall survival compared to non-obese patients. When considering these findings, we must take into account that 9 out of 11 evaluated studies included advanced/metastatic patients. Cancer cachexia mechanisms are not completely defined yet, but several evidences showed that the systemic inflammatory status induced either by the tumor and host-response is a key moment in its developing230. Lung cancers are indeed known to be aggressive diseases, and advanced patients are usually accompanied by poorer performance status and significant weight loss at the time of diagnosis, which underlies a systemic inflammatory response231. According to this view, a post-hoc analysis from three international phase III studies including advanced non-small cell lung cancer patients who received a platinum-based, first-line chemotherapy, revealed that weight gain during treatment was significantly associated with better clinical outcomes232. Intriguingly, a recent study showed that a decrease in BMI at lung cancer diagnosis (from the early adulthood) is a consistent marker of poor survival183. Considering these observations, an increased BMI might be considered a protective feature and potentially a marker of functional reserve for lung cancer patients. Recent evidences suggest a positive predictive role of an increased BMI for cancer patients receiving immune checkpoint inhibitors across different malignancies, including lung cancer54. Interestingly, the only study with lung cancer patients who received an immune checkpoint inhibitor (atezolizumab), revealed that the OS benefit for obese patients was significantly higher within the atezolizumabtreated cohort, compared to the doxetaxel treated cohort110. However, we have to remark that no significant OS difference was found across BMI categories within the docetaxel treated patients. Similar mechanisms can be applied to the finding of a survival benefit for obese melanoma patients from the single included study. Several evidences indeed confirmed that a high BMI might be considered a surrogate marker of clinical benefit from immune checkpoint inhibitors for advanced melanoma patients23,32,34.

Interestingly, also obese RCC patients revealed to have a significantly longer OS compared to the respective non-obese cohorts. It has been already hypotesized that the perinephric white adipose tissue act as a reservoir of activated immune cells with increased characteristics of hypoxia, infiltration of Th1 cells, regulatory T cells, dendritic cells, and type 1 macrophages. However, only one out of six studies inclued patient receiving immunotherapy23,52,36.

Intriguingly, we found that the association between obesity and better clinical outcomes seems to be confirmed for those malignancies in which immune checkpoint inhibitors have first (and strongly) proved to be effective, despite studies involving patients receiving immune checkpoint inhibitors are poorly represented in this meta-analysis. Such results, might probably be an epiphenomenon, however we are allowed to speculate that the white adipose tissue could be considered an immune organ, which somehow plays a role in the anti-tumor immune response. It has been observed that the adipocyte-derived hormone leptin could alter T-cell function, resulting in improved response to anti-PD-1 therapy11. Moreover, another preclinical study reported that white adipose tissue acts as a reservoir for a peculiar population of memory T cells, which elicitate some effective responses in case of antigenic re-exposure during infections (and why not in case of exposure to cancer-specific antigens?)2,37.

Obese patients are also at increased risk of reduced physical activity. Various studies highlighted this concept. Physical activity declines over time in obese patients23,82,39. In particular, physical activity is strictly correlated with breast cancer and colorectal cancer mortality240,241. Therefore physical (in)activity should be a major target of obesity prevention and treatment in particular in cancer patients. Type 2 diabetes mellitus is strongly associated with obesity in the metabolic syndrome. More than 80 percent of cases of type 2 diabetes can be attributed to obesity, which may also account for many diabetes-related deaths. The association between BMI and cause-specific mortality was also illustrated in the Prospective Studies Collaboration analysis242. In the upper BMI range (25 to 50 kg/m2), each 5 kg/m2 increase in BMI was associated with a significant increase in mortality from coronary heart disease (CHD), stroke, diabetes mellitus, chronic kidney disease, and many cancers. In the same analysis, subjects with BMI below 22.5 kg/m2 had higher mortality compared with subjects with a BMI of 22.5 to 25 kg/m2. The excess mortality was predominantly due to smoking-related diseases (respiratory and cancer). Despite there are no clear recommendation about dosing of chemotherapy in obese patients, caution is recommended for high risk regimens243. The hypothesis that a reduced dose according to ideal body weight may lead to a reduced outcome cannot be confirmed by prospective studies but may be considered as potential reason for the observed results in some settings (e.g. breast cancer). In a pooled analysis of toxicity in obese vs non-obese rates of toxic effects were similar or lower in obese patients244.

However, this meta‐analysis has several limitations. First, we combined data of obese patients and compared prognosis with different non-obese subjects (normal weight or normal weight + overweight). Second, accurate measures of weight and height are always a challenge in observational studies. The evaluation is often before diagnosis but in some studies timing of obesity diagnosis is not described. Obese subjects have a general poor prognosis in term of overall mortality and non-cancer mortality, so it seems obvious that their prognosis is dismal. However, almost all studies provided a multivariate analysis according to main prognostic factor for oncological outcome so that obesity remain generally an independent prognostic factor in cancer patients. Duration of follow up, treatments received, and countries are heterogeneous even if subgroup analysis does not explain results with these different variables. Lastly, this meta‐analysis compared mortality between patients belonging to a fixed category of obesity (>30 kg/m2) and thus we are not able to provide effect size per unit increment of kg/m2.

In conclusion, results of this meta-analysis confirm and reinforce the notion that obesity is a competing risk factor for overall and cancer specific mortality and relapse in various cancers treated with curative intent or for metastatic disease except for lung cancer and melanoma where it has an apparent protective effect (obesity paradox). It is advised that in the future, oncologists increase their efforts to manage patients into multidisciplinary teams for care and cure of both cancer and obesity. Improving lifestyle (e.g., physical activity, calories intake, care/prevention of cardiovascular complications), more intensive follow-ups of cancer in obese, and adequate dose of medical therapies are all proved measures that may improve prognosis of obese cancer patients.

Data Availability

Not applicable

References

  1. 1.↵
    Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019. doi:10.1016/j.metabol.2018.09.005
    OpenUrlCrossRefPubMed
  2. 2.↵
    Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: Systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016. doi:10.1136/bmj.i2156
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Lavie CJ, Sharma A, Alpert MA, et al. Update on Obesity and Obesity Paradox in Heart Failure. Prog Cardiovasc Dis. 2016. doi:10.1016/j.pcad.2015.12.003
    OpenUrlCrossRefPubMed
  4. 4.↵
    Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009. doi:10.1186/1471-2458-9-88
    OpenUrlCrossRefPubMed
  5. 5.↵
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. N Engl J Med. 2003. doi:10.1056/NEJMoa021423
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Greenlee H, Shi Z, Sardo Molmenti CL, Rundle A, Tsai WY. Trends in obesity prevalence in adults with a history of cancer: Results from the US National Health Interview Survey, 1997 to 2014. J Clin Oncol. 2016. doi:10.1200/JCO.2016.66.4391
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Gallagher EJ, LeRoith D. Obesity and diabetes: The increased risk of cancer and cancer-related mortality. Physiol Rev. 2015. doi:10.1152/physrev.00030.2014
    OpenUrlCrossRefPubMed
  8. 8.↵
    Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011. doi:10.1038/nrc3174
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Lennon H, Sperrin M, Badrick E, Renehan AG. The Obesity Paradox in Cancer: a Review. Curr Oncol Rep. 2016. doi:10.1007/s11912-016-0539-4
    OpenUrlCrossRefPubMed
  10. 10.↵
    Shachar SS, Williams GR. The obesity paradox in cancer-moving beyond BMI. Cancer Epidemiol Biomarkers Prev. 2017. doi:10.1158/1055-9965.EPI-16-0439
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019. doi:10.1038/s41591-018-0221-5
    OpenUrlCrossRefPubMed
  12. 12.↵
    Li S, Wang Z, Huang J, et al. Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: Does the “obesity paradox” really exist? Eur J Cardio-thoracic Surg. 2017. doi:10.1093/ejcts/ezw386
    OpenUrlCrossRefPubMed
  13. 13.↵
    Bagheri M, Speakman JR, Shemirani F, Djafarian K. Renal cell carcinoma survival and body mass index: A dose-response meta-analysis reveals another potential paradox within a paradox. Int J Obes. 2016. doi:10.1038/ijo.2016.171
    OpenUrlCrossRef
  14. 14.↵
    Shen N, Fu P, Cui B, Bu C-Y, Bi J-W. Associations between body mass index and the risk of mortality from lung cancer: A dose-response PRISMA-compliant meta analysis of prospective cohort studies. Med. 2017.
  15. 15.↵
    Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014. doi:10.1093/annonc/mdu042
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    Wu S, Liu J, Wang X, Li M, Gan Y, Tang Y. Association of obesity and overweight with overall survival in colorectal cancer patients: a meta-analysis of 29 studies. Cancer Causes Control. 2014. doi:10.1007/s10552-014-0450-y
    OpenUrlCrossRefPubMed
  17. 17.↵
    Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: A systematic review and meta-analysis. Cancer Prev Res. 2012. doi:10.1158/19406207.CAPR-12-0048
    OpenUrlCrossRef
  18. 18.↵
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. In: Journal of Clinical Epidemiology. Vol 62.; 2009:e1–34. doi:10.1016/j.jclinepi.2009.06.006
    OpenUrlCrossRefPubMed
  19. 19.↵
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA TS. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2010;283(15):2008–2012. doi:10.1001/jama.283.15.2008
    OpenUrlCrossRef
  20. 20.↵
    Wells GA, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical[_]epidemiology/oxford.asp. Accessed 13 Aug 2014. Ottawa Hosp Res Inst. 2014.
  21. 21.↵
    Abdel-Rahman O. Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the PLCO trial. Expert Rev Respir Med. 2019;13(10):1029–1035. doi:10.1080/17476348.2019.1656532
    OpenUrlCrossRefPubMed
  22. 22.↵
    Abdullah A, Wolfe R, Stoelwinder JU, et al. The number of years lived with obesity and the risk of all-cause and cause-specific mortality. Int J Epidemiol. 2011;40(4):985–996. doi:10.1093/ije/dyr018
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    Abrahamson PE, Gammon MD, Lund MJ, et al. General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1871–1877. doi:10.1158/1055-9965.EPI-06-0356
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    Abubakar M, Sung H, Bcr D, et al. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: Analysis of 3012 women from an indigenous Asian population. Breast Cancer Res. 2018;20(1):1–14. doi:10.1186/s13058-018-1033-8
    OpenUrlCrossRef
  25. 25.↵
    Ademuyiwa FO, Groman A, O’Connor T, Ambrosone C, Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer. 2011;117(18):4132–4140. doi:10.1002/cncr.26019
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    Akinyemiju T, Moore JX, Pisu M, et al. Mortality among Blacks and Whites. 2018;26(1):193–201. doi:10.1002/oby.22067.A
    OpenUrlCrossRef
  27. 27.↵
    Beasley JM, Kwan ML, Chen WY, et al. Meeting the physical activity guidelines and survival after breast cancer: Findings from the after breast cancer pooling project. Breast Cancer Res Treat. 2012. doi:10.1007/s10549-011-1770-1
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    Aldrich MC, Grogan EL, Munro HM, Signorello LB, Blot WJ. Stage-adjusted lung cancer survival does not differ between low-income blacks and whites. J Thorac Oncol. 2013;8(10):1248–1254. doi:10.1097/JTO.0b013e3182a406f6
    OpenUrlCrossRefPubMed
  29. 29.↵
    Alsaker MDK, Opdahl S, Åsvold BO, Romundstad PR, Vatten LJ. The association of reproductive factors and breastfeeding with long term survival from breast cancer. Breast Cancer Res Treat. 2011;130(1):175–182. doi:10.1007/s10549-011-1566-3
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    Arce-Salinas C, Aguilar-Ponce JL, Villarreal-Garza C, et al. Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients. Breast Cancer Res Treat. 2014;146(1):183–188. doi:10.1007/s10549-014-2977-8
    OpenUrlCrossRefPubMed
  31. 31.↵
    Arem H, Park Y, Pelser C, et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. J Natl Cancer Inst. 2013;105(5):342–349.doi:10.1093/jnci/djs530
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    Ata N, Ayloo S, Tsung A, Molinari M. Recipient obesity does not affect survival after deceased donor liver transplantation for hepatocellular carcinoma. A national retrospective cohort study in the United States. Hpb. 2019;21(1):67–76. doi:10.1016/j.hpb.2018.06.1797
    OpenUrlCrossRef
  33. 33.↵
    Bandera EV., Lee VS, Rodriguez-Rodriguez L, Bethan Powell C, Kushi LH. Impact of chemotherapy dosing on ovarian cancer survival according to body mass index. JAMA Oncol. 2015;1(6):737–745. doi:10.1001/jamaoncol.2015.1796
    OpenUrlCrossRefPubMed
  34. 34.↵
    Hung CY, Lai CC, Chen PT, et al. Impact of body mass index on long-term survival outcome in Asian populations with solid cancer who underwent curative-intent surgery: A six-year multicenter observational cohort study. J Cancer. 2018;9(18):3316–3325. doi:10.7150/jca.25729
    OpenUrlCrossRef
  35. 35.↵
    Bassett JK, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer. 2012;131(7):1711–1719. doi:10.1002/ijc.27414
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    Blair CK, Wiggins CL, Nibbe AM, et al. Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. npj Breast Cancer. 2019;5(1):1–7. doi:10.1038/s41523-019-0128-4
    OpenUrlCrossRefPubMed
  37. 37.↵
    Boggs DA, Rosenberg L, Cozier YC, et al. General and abdominal obesity and risk of death among black women. N Engl J Med. 2011;365(10):901–908. doi:10.1056/NEJMoa1104119
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    Bonn SE, Wiklund F, Sjölander A, et al. Body mass index and weight change in men with prostate cancer: Progression and mortality. Cancer Causes Control. 2014;25(8):933–943. doi:10.1007/s10552-014-0393-3
    OpenUrlCrossRefPubMed
  39. 39.↵
    Boyle T, Fritschi L, Platell C, Heyworth J. Lifestyle factors associated with survival after colorectal cancer diagnosis. Br J Cancer. 2013;109(3):814–822. doi:10.1038/bjc.2013.310
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    Braithwaite D, Satariano WA, Sternfeld B, et al. Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst. 2010;102(19):1468–1477. doi:10.1093/jnci/djq344
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    Clark W, Siegel EM, Chen YA, et al. Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am Coll Surg. 2013. doi:10.1016/j.jamcollsurg.2013.01.007
    OpenUrlCrossRef
  42. 42.↵
    Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control. 2012. doi:10.1007/s10552012-9989-7
    OpenUrlCrossRef
  43. 43.
    Caan BJ, Kwan ML. Pre-diagnosis body mass index, post-diagnosis weight change. 2010;19(10):1319–1328. doi:10.1007/s10552-008-9203-0.Pre-diagnosis
    OpenUrlCrossRef
  44. 44.
    Campbell PT, Newton CC, Newcomb PA, et al. Association between body mass index and mortality for colorectal cancer survivors: Overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev. 2015;24(8):1229–1238. doi:10.1158/1055-9965.EPI-15-0094
    OpenUrlAbstract/FREE Full Text
  45. 45.
    Carr BI, Giannelli G, Guerra V, et al. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. Int J Biol Markers. 2018;33(4):423–431. doi:10.1177/1724600818776838
    OpenUrlCrossRef
  46. 46.
    Cecchini RS, Swain SM, Costantino JP, et al. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiol Biomarkers Prev. 2016;25(1):51–59. doi:10.1158/1055-9965.EPI-15-0334-T
    OpenUrlAbstract/FREE Full Text
  47. 47.
    Cespedes Feliciano EM, Kwan ML, Kushi LH, et al. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer. Cancer. 2017;123(13):2535–2542. doi:10.1002/cncr.30637
    OpenUrlCrossRef
  48. 48.
    Chang S, Alderfer JR, Asmar L, Buzdar AU. Inflammatory breast cancer survival: The role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat. 2000;64(2):157–163. doi:10.1023/A:1006489100283
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.
    Chen X, Lu W, Zheng W, et al. Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat. 2010;122(3):823–833. doi:10.1007/s10549-009-0708-3
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    Chromecki TF, Cha EK, Fajkovic H, et al. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int. 2013;111(2):249–255. doi:10.1111/j.1464-410X.2012.11322.x
    OpenUrlCrossRef
  51. 51.↵
    Chung IY, Lee JW, Lee JS, et al. Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer. PLoS One. 2017;12(3):1–11. doi:10.1371/journal.pone.0170311
    OpenUrlCrossRefPubMed
  52. 52.↵
    Connor AE, Visvanathan K, Baumgartner KB, et al. Ethnic differences in the relationships between diabetes, early age adiposity and mortality among breast cancer survivors: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2016;157(1):167–178. doi:10.1007/s10549-016-3810-3
    OpenUrlCrossRef
  53. 53.
    Conroy SM, Maskarinec G, Wilkens LR, White KK, Henderson BE, Kolonel LN. Obesity and breast cancer survival in ethnically diverse postmenopausal women: The Multiethnic Cohort Study. Breast Cancer Res Treat. 2011;129(2):565–574. doi:10.1007/s10549-011-1468-4
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    Cortellini A, Bersanelli M, Buti S, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable. J Immunother Cancer. 2019;7(1):1–11. doi:10.1186/s40425-019-0527-y
    OpenUrlAbstract/FREE Full Text
  55. 55.
    Crozier JA, Moreno-Aspitia A, Ballman K V., Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer. 2013;119(13):2447–2454. doi:10.1002/cncr.28051
    OpenUrlCrossRef
  56. 56.
    Copson ER, Cutress RI, Maishman T, et al. Obesity and the outcome of young breast cancer patients in the UK: The POSH study. Ann Oncol. 2015;26(1):101–112. doi:10.1093/annonc/mdu509
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.
    Dahdaleh FS, Sherman SK, Poli EC, et al. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. Surg (United States). 2018;164(6):1223–1229. doi:10.1016/j.surg.2018.06.044
    OpenUrlCrossRef
  58. 58.
    Dal Maso L, Zucchetto A, Talamini R, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 2008;123(9):2188–2194. doi:10.1002/ijc.23747
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.
    Dalal S, Hui D, Bidaut L, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: A pilot study. J Pain Symptom Manage. 2012;44(2):181–191. doi:10.1016/j.jpainsymman.2011.09.010
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer. 2012;12(5):364–372. doi:10.1016/j.clbc.2012.07.013
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    Dickerman BA, Ahearn TU, Giovannucci E, et al. Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer. 2017;141(5):933–944. doi:10.1002/ijc.30803
    OpenUrlCrossRef
  62. 62.
    Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: Rtog 85-31. J Clin Oncol. 2009. doi:10.1200/JCO.2007.12.3752
    OpenUrlAbstract/FREE Full Text
  63. 63.
    Dignam JJ. Obesity, Tamoxifen Use, and Outcomes in Women With Estrogen Receptor-Positive Early-Stage Breast Cancer. CancerSpectrum Knowl Environ. 2003;95(19):1467–1476. doi:10.1093/jnci/djg060
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.
    Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98(22):1647–1654. doi:10.1093/jnci/djj442
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.
    Dignam JJ, Wieand K, Johnson KA, et al. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2006;97(3):245–254. doi:10.1007/s10549-005-9118-3
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.
    Doria-Rose VP, Newcomb PA, Morimoto LM, Hampton JM, Trentham-Dietz A. Body mass index and the risk of death following the diagnosis of colorectal cancer in postmenopausal women (United States). Cancer Causes Control. 2006;17(1):63–70. doi:10.1007/s10552-005-0360-0
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.
    Drake I, Gullberg B, Sonestedt E, et al. Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting. Int J Cancer. 2017;141(6):1170–1180. doi:10.1002/ijc.30824
    OpenUrlCrossRef
  68. 68.
    Elwood JM, Tin Tin S, Kuper-Hommel M, Lawrenson R, Campbell I. Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study. BMC Cancer. 2018;18(1):1–13. doi:10.1186/s12885-017-3971-4
    OpenUrlCrossRefPubMed
  69. 69.
    Emaus A, Veierød MB, Tretli S, et al. Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat. 2010;121(3):651–660. doi:10.1007/s10549-009-0603-y
    OpenUrlCrossRefPubMedWeb of Science
  70. 70.↵
    Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007;109(6):1192–1202. doi:10.1002/cncr.22534
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM. Anthropometric measurements and survival after a prostate cancer diagnosis. Br J Cancer. 2018;118(4):607–610. doi:10.1038/bjc.2017.440
    OpenUrlCrossRef
  72. 72.
    Fedirko V, Romieu I, Aleksandrova K, et al. Pre-diagnostic anthropometry and survival after colorectal cancer diagnosis in Western European populations. Int J Cancer. 2014;135(8):1949–1960. doi:10.1002/ijc.28841
    OpenUrlCrossRefPubMed
  73. 73.
    Feliciano EMC, Kroenke CH, Meyerhardt JA, et al. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. JAMA Oncol. 2017;3(12):e172319. doi:10.1001/jamaoncol.2017.2319
    OpenUrlCrossRef
  74. 74.
    Ferro M, Vartolomei MD, Russo GI, et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol. 2019;37(3):507–514. doi:10.1007/s00345-0182397-1
    OpenUrlCrossRef
  75. 75.
    Froehner M, Kellner AE, Koch R, Baretton GB, Hakenberg OW, Wirth MP. A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. BMC Urol. 2014;14(1):1–8. doi:10.1186/1471-2490-14-28
    OpenUrlCrossRefPubMed
  76. 76.
    Frumovitz M, Jhingran A, Soliman PT, Klopp AH, Schmeler KM, Eifel PJ. Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. Obstet Gynecol. 2014;124(6):1098–1104. doi:10.1097/AOG.0000000000000558
    OpenUrlCrossRefPubMed
  77. 77.
    Genkinger JM, Kitahara CM, Bernstein L, et al. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Ann Oncol. 2015;26(11):2257–2266. doi:10.1093/annonc/mdv355
    OpenUrlCrossRefPubMed
  78. 78.
    Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007;109(6):1192–1202. doi:10.1002/cncr.22534
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.
    Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin- and obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations. J Clin Oncol. 2012;30(2):164–171. doi:10.1200/JCO.2011.36.2723
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    Grossberg AJ, Chamchod S, Fuller CD, et al. Association of body composition with survival and locoregional control of radiotherapy-treated head and neck squamous cell carcinoma. JAMA Oncol. 2016;2(6):782–789. doi:10.1001/jamaoncol.2015.6339
    OpenUrlCrossRef
  81. 81.↵
    Sinicrope FA, Foster NR, Yothers G, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013. doi:10.1002/cncr.27938
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer. 2007;110(7):1478–1484. doi:10.1002/cncr.22932
    OpenUrlCrossRefPubMed
  83. 83.
    McMahon BJ, Bruden D, Townshend-Bulson L, et al. Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death. Clin Gastroenterol Hepatol. 2017. doi:10.1016/j.cgh.2016.10.012
    OpenUrlCrossRef
  84. 84.
    Han M, Trock BJ, Partin AW, et al. The impact of preoperative erectile dysfunction on survival after radical prostatectomy. BJU Int. 2010;106(11):1612–1617. doi:10.1111/j.1464-410X.2010.09472.x
    OpenUrlCrossRefPubMed
  85. 85.
    Han X, Stevens J, Truesdale KP, et al. Body mass index at early adulthood, subsequent weight change and cancer incidence and mortality. Int J Cancer. 2014;135(12):2900–2909. doi:10.1002/ijc.28930
    OpenUrlCrossRefPubMed
  86. 86.
    He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SCJ. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2012;23(7):1771–1780. doi:10.1093/annonc/mdr534
    OpenUrlCrossRefPubMedWeb of Science
  87. 87.
    Hellmann SS, Thygesen LC, Tolstrup JS, Grønbæk M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: Results from a prospective cohort study. Eur J Cancer Prev. 2010;19(5):366–373. doi:10.1097/CEJ.0b013e32833b4828
    OpenUrlCrossRefPubMed
  88. 88.
    His M, Fagherazzi G, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Dossus L. Prediagnostic body size and breast cancer survival in the E3N cohort study. Int J Cancer. 2016;139(5):1053–1064. doi:10.1002/ijc.30158
    OpenUrlCrossRef
  89. 89.
    Ho T, Gerber L, Aronson WJ, et al. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: Biology or Technique? Results from the SEARCH database. Eur Urol. 2012;62(5):910–916. doi:10.1016/j.eururo.2012.08.015
    OpenUrlCrossRefPubMed
  90. 90.↵
    Houdek MT, Griffin AM, Ferguson PC, Wunder JS. Morbid Obesity Increases the Risk of Postoperative Wound Complications, Infection, and Repeat Surgical Procedures Following Upper Extremity Limb Salvage Surgery for Soft Tissue Sarcoma. Hand. 2019;14(1):114–120. doi:10.1177/1558944718797336
    OpenUrlCrossRef
  91. 91.↵
    Hu Qinchao, Peng J, Chen X, et al. Obesity and genes related to lipid metabolism predict poor survival in oral squamous cell carcinoma. Oral Oncol. 2019;89(December 2018):14–22. doi:10.1016/j.oraloncology.2018.12.006
    OpenUrlCrossRef
  92. 92.
    Rosenberg L, Czene K, Hall P. Obesity and poor breast cancer prognosis: An illusion because of hormone replacement therapy. Br J Cancer. 2009;100(9):1486–1491. doi:10.1038/sj.bjc.6605025
    OpenUrlCrossRefPubMedWeb of Science
  93. 93.
    Ruterbusch JJ, Ali-Fehmi R, Olson SH, et al. The influence of comorbid conditions on racial disparities in endometrial cancer survival. Am J Obstet Gynecol. 2014. doi:10.1016/j.ajog.2014.06.036
    OpenUrlCrossRef
  94. 94.
    Iyengar NM, Kochhar A, Morris PG, et al. NIH Public Access. 2015;120(7):983–991. doi:10.1002/cncr.28532.Impact
    OpenUrlCrossRef
  95. 95.
    Izumida T, Nakamura Y, Ishikawa S. Impact of body mass index and metabolically unhealthy status on mortality in the Japanese general population: The JMS cohort study. PLoS One. 2019;14(11):1–16. doi:10.1371/journal.pone.0224802
    OpenUrlCrossRefPubMed
  96. 96.
    Janssen SJ, van der Heijden AS, van Dijke M, et al. 2015 Marshall Urist Young Investigator Award: Prognostication in Patients With Long Bone Metastases: Does a Boosting Algorithm Improve Survival Estimates? Clin Orthop Relat Res. 2015;473(10):3112–3121. doi:10.1007/s11999-015-4446-z
    OpenUrlCrossRefPubMed
  97. 97.
    Jayasekara H, English DR, Haydon A, et al. Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. Int J Cancer. 2018;142(2):238–250. doi:10.1002/ijc.31049
    OpenUrlCrossRef
  98. 98.
    Jenkins DA, Bowden J, Robinson HA, et al. Adiposity-mortality relationships in type 2 diabetes, coronary heart disease, and Cancer Subgroups in the UK Biobank, and their modification by smoking. Diabetes Care. 2018;41(9):1878–1886. doi:10.2337/dc17-2508
    OpenUrlAbstract/FREE Full Text
  99. 99.
    Jeon YW, Kang SH, Park MH, Lim W, Cho SH, Suh YJ. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. BMC Cancer. 2015;15(1). doi:10.1186/s12885-015-1879-4
    OpenUrlCrossRef
  100. 100.↵
    Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol. 2013;24(10):2506–2514. doi:10.1093/annonc/mdt224
    OpenUrlCrossRefPubMed
  101. 101.↵
    Kaidar-Person O, Badarna H, Bar-Sela G. Bevacizumab for metastatic colon cancer: Does patient BMI influence survival? Anticancer Drugs. 2015;26(3):363–366. doi:10.1097/CAD.0000000000000201
    OpenUrlCrossRef
  102. 102.
    Kalb M, Langheinrich MC, Merkel S, et al. Influence of body mass index on long-term outcome in patients with rectal cancer-a single centre experience. Cancers (Basel). 2019;11(5). doi:10.3390/cancers11050609
    OpenUrlCrossRef
  103. 103.
    Katzmarzyk PT, Reeder BA, Elliott S, et al. Body mass index and risk of cardiovascular disease, cancer and all-cause mortality. Can J Public Heal. 2012;103(2):147–151. doi:10.1007/bf03404221
    OpenUrlCrossRef
  104. 104.
    Kawai M, Tomotaki A, Miyata H, et al. Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry. Cancer Med. 2016;5(6):1328–1340. doi:10.1002/cam4.678
    OpenUrlCrossRef
  105. 105.
    Keegan THM, Milne RL, Andrulis IL, et al. Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: Results from the breast cancer family registry. Breast Cancer Res Treat. 2010;123(2):531–542. doi:10.1007/s10549-010-0774-6
    OpenUrlCrossRefPubMedWeb of Science
  106. 106.
    Keizman D, Gottfried M, Ish-Shalom M, et al. Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Oncologist. 2014;19(1):51–60.doi:10.1634/theoncologist.2012-0335
    OpenUrlAbstract/FREE Full Text
  107. 107.
    Kelly SP, Graubard BI, Andreotti G, Younes N, Cleary SD, Cook MB. Prediagnostic body mass index trajectories in relation to prostate cancer incidence and mortality in the PLCO cancer screening trial. J Natl Cancer Inst. 2017;109(3):1–9. doi:10.1093/jnci/djw225
    OpenUrlCrossRefPubMed
  108. 108.
    Kenfield SA, Batista JL, Jahn JL, et al. Development and Application of a Lifestyle Score for Prevention of Lethal Prostate Cancer. J Natl Cancer Inst. 2016;108(3). doi:10.1093/jnci/djv329
    OpenUrlCrossRefPubMed
  109. 109.
    Khan S, Cai J, Nielsen ME, et al. The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC. Prostate. 2017;77(8):878–887. doi:10.1002/pros.23342
    OpenUrlCrossRef
  110. 110.↵
    Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.5241
    OpenUrlCrossRef
  111. 111.↵
    Kitahara CM, Flint AJ, Berrington de Gonzalez A, et al. Association between Class III Obesity (BMI of 40-59 kg/m2) and Mortality: A Pooled Analysis of 20 Prospective Studies. PLoS Med. 2014;11(7). doi:10.1371/journal.pmed.1001673
    OpenUrlCrossRefPubMed
  112. 112.
    Minlikeeva AN, Cannioto R, Jensen A, et al. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes Control. 2019. doi:10.1007/s10552-019-01157-3
    OpenUrlCrossRef
  113. 113.
    Kotsopoulos J, Moody JRK, Fan I, et al. Height, weight, BMI and ovarian cancer survival. Gynecol Oncol. 2012;127(1):83–87. doi:10.1016/j.ygyno.2012.05.038
    OpenUrlCrossRefPubMed
  114. 114.
    Kristensen AB, Hare-Bruun H, Høgdall CK, Rudnicki M. Influence of Body Mass Index on Tumor Pathology and Survival in Uterine Cancer: A Danish Register Study. Int J Gynecol Cancer. 2017;27(2):281–288. doi:10.1097/IGC.0000000000000874
    OpenUrlAbstract/FREE Full Text
  115. 115.
    Kwan ML, Chen WY, Kroenke CH, et al. Pre-diagnosis body mass index and survival after breast cancer in the after Breast Cancer Pooling Project. Breast Cancer Res Treat. 2012;132(2):729–739. doi:10.1007/s10549-011-1914-3
    OpenUrlCrossRefPubMedWeb of Science
  116. 116.
    Kwan ML, John EM, Caan BJ, et al. Obesity and mortality after breast cancer by Race/Ethnicity: The california breast cancer survivorship consortium. Am J Epidemiol. 2014;179(1):95–111. doi:10.1093/aje/kwt233
    OpenUrlCrossRefPubMed
  117. 117.
    Ladoire S, Dalban C, Roché H, et al. Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: A pooled analysis of two randomised trials. Eur J Cancer. 2014;50(3):506–516. doi:10.1016/j.ejca.2013.11.013
    OpenUrlCrossRefPubMed
  118. 118.
    Larsen SB, Kroman N, Ibfelt EH, Christensen J, Tjønneland A, Dalton SO. Influence of metabolic indicators, smoking, alcohol and socioeconomic position on mortality after breast cancer. Acta Oncol (Madr). 2015;54(5):780–788. doi:10.3109/0284186X.2014.998774
    OpenUrlCrossRef
  119. 119.
    Siegel EM, Nabors LB, Thompson RC, et al. Prediagnostic body weight and survival in high grade glioma. J Neurooncol. 2013. doi:10.1007/s11060-013-1150-2
    OpenUrlCrossRef
  120. 120.↵
    Lee WK, Byun SS, Kim HH, et al. Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: A multicenter study. Int J Urol. 2010;17(11):898–904. doi:10.1111/j.1442-2042.2010.02630.x
    OpenUrlCrossRefPubMed
  121. 121.↵
    Gama RR, Song Y, Zhang Q, et al. Body mass index and prognosis in patients with head and neck cancer. Head Neck. 2017. doi:10.1002/hed.24760
    OpenUrlCrossRef
  122. 122.
    Leung CC, Lam TH, Yew WW, Chan WM, Law WS, Tam CM. Lower lung cancer mortality in obesity. Int J Epidemiol. 2011;40(1):174–182. doi:10.1093/ije/dyq134
    OpenUrlCrossRefPubMedWeb of Science
  123. 123.
    Li D, Morris JS, Day RS, Bondy ML, Abbruzzese JL. Body Mass Index and Risk, Age of Onset,. JAMA. 2014;301(24):2553–2562.
    OpenUrl
  124. 124.
    Liss M, Natarajan L, Hasan A, Noguchi JL, White M, Parsons JK. Physical Activity Decreases Kidney Cancer Mortality. Curr Urol. 2017;10(4):193–198. doi:10.1159/000447180
    OpenUrlCrossRef
  125. 125.
    Loi S, Milne RL, Friedlander ML, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1686–1691. doi:10.1158/1055-9965.EPI-05-0042
    OpenUrlAbstract/FREE Full Text
  126. 126.
    Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039–1047. doi:10.1016/S1470-2045(08)70235-3
    OpenUrlCrossRefPubMedWeb of Science
  127. 127.
    Maj-Hes AB, Mathieu R, Özsoy M, et al. Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. Urol Oncol Semin Orig Investig. 2017;35(7):460.e1–460.e8. doi:10.1016/j.urolonc.2017.01.022
    OpenUrlCrossRef
  128. 128.
    Martini DJ, Kline MR, Liu Y, et al. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer. 2020;126(3):575–582. doi:10.1002/cncr.32576
    OpenUrlCrossRef
  129. 129.
    Maskarinec G, Pagano I, Lurie G, Bantum E, Gotay CC, Issell BF. Factors affecting survival among women with breast cancer in Hawaii. J Women’s Heal. 2011;20(2):231–237. doi:10.1089/jwh.2010.2114
    OpenUrlCrossRefPubMed
  130. 130.↵
    Mathur AK, Ghaferi AA, Sell K, Sonnenday CJ, Englesbe MJ, Welling TH. Influence of body mass index on complications and oncologic outcomes following hepatectomy for malignancy. J Gastrointest Surg. 2010;14(5):849–857. doi:10.1007/s11605-010-1163-5
    OpenUrlCrossRefPubMed
  131. 131.↵
    Matsuo K, Moeini A, Cahoon SS, et al. Weight Change Pattern and Survival Outcome of Women with Endometrial Cancer. Ann Surg Oncol. 2016;23(9):2988–2997. doi:10.1245/s10434-016-5237-9
    OpenUrlCrossRef
  132. 132.
    Song X, Pitkäniemi J, Gao W, et al. Relationship between body mass index and mortality among Europeans. Eur J Clin Nutr. 2012;66(2):156–165. doi:10.1038/ejcn.2011.145
    OpenUrlCrossRefPubMed
  133. 133.
    Mazzarella L, Disalvatore D, Bagnardi V, et al. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. Eur J Cancer. 2013;49(17):3588–3597. doi:10.1016/j.ejca.2013.07.016
    OpenUrlCrossRef
  134. 134.
    McCullough LE, Chen J, Cho YH, et al. DNA methylation modifies the association between obesity and survival after breast cancer diagnosis. Breast Cancer Res Treat. 2016;156(1):183–194. doi:10.1007/s10549-016-3724-0
    OpenUrlCrossRef
  135. 135.
    McCullough ML, Feigelson HS, Diver WR, Patel A V., Thun MJ, Calle EE. Risk factors for fatal breast cancer in African-American women and white women in a large US prospective cohort. Am J Epidemiol. 2005;162(8):734–742. doi:10.1093/aje/kwi278
    OpenUrlCrossRefPubMedWeb of Science
  136. 136.
    Mcquade JL, Daniel CR, Hess PKR, et al. HHS Public Access. 2018;19(3):310–322. doi:10.1016/S1470-2045(18)30078-0.The
    OpenUrlCrossRefPubMed
  137. 137.
    Sorbye H, Mauer M, Gruenberger T, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg. 2012. doi:10.1097/SLA.0b013e3182456aa2
    OpenUrlCrossRefPubMed
  138. 138.
    Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2645–2652. doi:10.1200/JCO.2010.33.4441
    OpenUrlAbstract/FREE Full Text
  139. 139.
    Meyer J, Rohrmann S, Bopp M, et al. Impact of smoking and excess body weight on overall and site-specific cancer mortality risk. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1516–1522. doi:10.1158/1055-9965.EPI-15-0415
    OpenUrlAbstract/FREE Full Text
  140. 140.↵
    Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98(3):484–495. doi:10.1002/cncr.11544
    OpenUrlCrossRefPubMedWeb of Science
  141. 141.↵
    Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from cancer and leukemia group B 89803. J Clin Oncol. 2008;26(25):4109–4115. doi:10.1200/JCO.2007.15.6687
    OpenUrlAbstract/FREE Full Text
  142. 142.
    Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from intergroup trial 0114. J Clin Oncol. 2004;22(4):648–657. doi:10.1200/JCO.2004.07.121
    OpenUrlAbstract/FREE Full Text
  143. 143.
    Møller H, Roswall N, Hemelrijck M Van, et al. Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark. Int J Cancer. 2015;136(8):1940–1947. doi:10.1002/ijc.29238
    OpenUrlCrossRefPubMed
  144. 144.
    Montgomery RB, Goldman B, Tangen CM, et al. Association of Body Mass Index With Response and Survival in Men With Metastatic Prostate Cancer: Southwest Oncology Group Trials 8894 and 9916. J Urol. 2007;178(5):1946–1951. doi:10.1016/j.juro.2007.07.026
    OpenUrlCrossRefPubMedWeb of Science
  145. 145.
    Morikawa T, Kuchiba A, Liao X, et al. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer. 2012;131(5):1169–1178. doi:10.1002/ijc.26495
    OpenUrlCrossRefPubMedWeb of Science
  146. 146.
    Tseng CH. Obesity paradox: Differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. Atherosclerosis. 2013;226(1):186–192. doi:10.1016/j.atherosclerosis.2012.09.004
    OpenUrlCrossRefPubMedWeb of Science
  147. 147.
    Xie HJ, Zhang X, Wei ZQ, Long H, Rong TH, Su XD. Effect of body mass index on survival of patients with stage I non-small cell lung cancer. Chin J Cancer. 2017;36(1):1–10. doi:10.1186/s40880-016-0170-7
    OpenUrlCrossRef
  148. 148.
    Nagle CM, Crosbie EJ, Brand A, et al. The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. Gynecol Oncol. 2018;150(1):99–105. doi:10.1016/j.ygyno.2018.04.006
    OpenUrlCrossRef
  149. 149.
    Nakagawa T, Toyazaki T, Chiba N, Ueda Y, Gotoh M. Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. Interact Cardiovasc Thorac Surg. 2016;23(4):560–566. doi:10.1093/icvts/ivw175
    OpenUrlCrossRefPubMed
  150. 150.↵
    Nechuta SJ, Shu XO, Li HL, et al. Combined impact of lifestyle-related factors on total and cause-specific mortality among chinese women: Prospective cohort study. PLoS Med. 2010;7(9). doi:10.1371/journal.pmed.1000339
    OpenUrlCrossRefPubMed
  151. 151.↵
    Nicholas Z, Hu N, Ying J, Soisson P, Dodson M, Gaffney DK. Impact of comorbid conditions on survival in endometrial cancer. Am J Clin Oncol Cancer Clin Trials. 2014;37(2):131–134. doi:10.1097/COC.0b013e318277d5f4
    OpenUrlCrossRef
  152. 152.
    Nichols HB, Trentham-dietz A, Egan KM, et al. Disease Mortality. 2010;18(5):14031409. doi:10.1158/1055-9965.EPI-08-1094.Body
    OpenUrlCrossRef
  153. 153.
    Nonemaker JM, Garrett-Mayer E, Carpenter MJ, et al. The Risk of Dying from Lung Cancer by Race: A Prospective Cohort Study in a Biracial Cohort in Charleston, South Carolina. Ann Epidemiol. 2009;19(5):304–310. doi:10.1016/j.annepidem.2008.12.017
    OpenUrlCrossRefPubMed
  154. 154.
    Nur U, El Reda D, Hashim D, Weiderpass E. A prospective investigation of oral contraceptive use and breast cancer mortality: Findings from the Swedish women’s lifestyle and health cohort. BMC Cancer. 2019;19(1):1–9. doi:10.1186/s12885-0195985-6
    OpenUrlCrossRef
  155. 155.
    Ogino S, Nosho K, Baba Y, et al. A Cohort study of STMN1 expression in colorectal cancer: Body mass index and prognosis. Am J Gastroenterol. 2009;104(8):2047–2056. doi:10.1038/ajg.2009.281
    OpenUrlCrossRefPubMedWeb of Science
  156. 156.
    Oh SW, Park CY, Lee ES, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study. Breast Cancer Res. 2011;13(2):R34. doi:10.1186/bcr2856
    OpenUrlCrossRefPubMed
  157. 157.
    Olson SH, Chou JF, Ludwig E, et al. Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer. 2010;127(10):2412–2419. doi:10.1002/ijc.25240
    OpenUrlCrossRefPubMed
  158. 158.
    Oudanonh T, Nabi H, Ennour-Idrissi K, Lemieux J, Diorio C. Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer. Int J Cancer. 2019;00. doi:10.1002/ijc.32621
    OpenUrlCrossRef
  159. 159.
    Pajares B, Pollán M, Martín M, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: A pooled analysis. Breast Cancer Res. 2013;15(6):1–14. doi:10.1186/bcr3572
    OpenUrlCrossRefWeb of Science
  160. 160.↵
    Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology. 2006;68(4):741–746. doi:10.1016/j.urology.2006.05.024
    OpenUrlCrossRefPubMedWeb of Science
  161. 161.↵
    Parr CL, Batty GD, Lam TH, et al. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: Pooled analyses of 424 519 participants. Lancet Oncol. 2010;11(8):741–752. doi:10.1016/S1470-2045(10)70141-8
    OpenUrlCrossRefPubMedWeb of Science
  162. 162.
    Patel GS, Ullah S, Beeke C, et al. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. Cancer Med. 2015;4(10):1461–1471. doi:10.1002/cam4.490
    OpenUrlCrossRef
  163. 163.
    Pelser C, Arem H, Pfeiffer RM, et al. Prediagnostic lifestyle factors and survival after colon and rectal cancer diagnosis in the National Institutes of Health (NIH)-AARP Diet and Health Study. Cancer. 2014;120(10):1540–1547. doi:10.1002/cncr.28573
    OpenUrlCrossRefPubMedWeb of Science
  164. 164.
    Pfeiler G, Stöger H, Dubsky P, et al. Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: An analysis of 1509 patients of the ABCSG-06 trial. Br J Cancer. 2013;108(7):1408–1414. doi:10.1038/bjc.2013.114
    OpenUrlCrossRefPubMedWeb of Science
  165. 165.
    Yu M-L, Asal NR, Geyer JR. Later recurrence and longer survival among obese patients with renal cell carcinoma. Cancer. 1991. doi:10.1002/10970142(19911001)68:73.0.CO;2-5
    OpenUrlCrossRef
  166. 166.
    Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 2007;25(17):2345–2351. doi:10.1200/JCO.2006.08.6819
    OpenUrlAbstract/FREE Full Text
  167. 167.
    Potharaju M, Mangaleswaran B, Mathavan A, et al. Body Mass Index as a Prognostic Marker in Glioblastoma Multiforme: A Clinical Outcome. Int J Radiat Oncol Biol Phys. 2018;102(1):204–209. doi:10.1016/j.ijrobp.2018.05.024
    OpenUrlCrossRef
  168. 168.
    Previs RA, Kilgore J, Craven R, et al. Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. Int J Gynecol Cancer. 2014;24(4):670–675. doi:10.1097/IGC.0000000000000109
    OpenUrlAbstract/FREE Full Text
  169. 169.
    Prizment AE, Flood A, Anderson KE, Folsom AR. anthropometric characteristics : the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2229–2237. doi:10.1158/1055-9965.EPI-10-0522.Survival
    OpenUrlAbstract/FREE Full Text
  170. 170.↵
    Probst-Hensch NM, Steiner JHB, Schraml P, et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: Association with hormonal factors and obesity. Clin Cancer Res. 2010;16(3):1025–1032. doi:10.1158/1078-0432.CCR-09-0957
    OpenUrlAbstract/FREE Full Text
  171. 171.↵
    Psutka SP, Boorjian SA, Moynagh MR, et al. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. J Urol. 2016;195(2):270–276. doi:10.1016/j.juro.2015.08.072
    OpenUrlCrossRefPubMed
  172. 172.
    Qi Y, Schild SE, Mandrekar SJ, et al. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol. 2009;4(9):1075–1082. doi:10.1097/JTO.0b013e3181ae27f5
    OpenUrlCrossRefPubMed
  173. 173.
    Roque DR, Taylor KN, Palisoul M, et al. Gemcitabine and Docetaxel Compared with Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma. Int J Gynecol Cancer. 2016;26(3):505–511. doi:10.1097/IGC.0000000000000634
    OpenUrlAbstract/FREE Full Text
  174. 174.
    Rudman SM, Gray KP, Batista JL, et al. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU Int. 2016;118(6):919–926. doi:10.1111/bju.13428
    OpenUrlCrossRef
  175. 175.
    Sanchez A, Furberg H, Kuo F, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol. 2020;21(2):283–293. doi:10.1016/S1470-2045(19)30797-1
    OpenUrlCrossRef
  176. 176.
    Sasazuki S, Inoue M, Tsuji I, et al. Body mass index and mortality from all causes and major causes in Japanese: Results of a Pooled analysis of 7 large-scale cohort studies. J Epidemiol. 2011;21(6):417–430. doi:10.2188/jea.JE20100180
    OpenUrlCrossRefPubMedWeb of Science
  177. 177.
    Schiffmann J, Salomon G, Tilki D, et al. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. Urol Oncol Semin Orig Investig. 2017;35(5):243–249. doi:10.1016/j.urolonc.2016.12.014
    OpenUrlCrossRef
  178. 178.
    Schlesinger S, Siegert S, Koch M, et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis. Cancer Causes Control. 2014;25(10):1407–1418. doi:10.1007/s10552-014-0435-x
    OpenUrlCrossRefPubMed
  179. 179.
    Seidelin UH, Ibfelt E, Andersen I, et al. Does stage of cancer, comorbidity or lifestyle factors explain educational differences in survival after endometrial cancer? A cohort study among Danish women diagnosed 2005–2009. Acta Oncol (Madr). 2016;55(6):680–685. doi:10.3109/0284186X.2015.1136750
    OpenUrlCrossRef
  180. 180.↵
    Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW. Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med. 1992;116(1):26–32. doi:10.7326/0003-4819-116-1-26
    OpenUrlCrossRefPubMedWeb of Science
  181. 181.↵
    Shah MS, Fogelman DR, Raghav KPS, et al. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer. 2015;121(17):2968–2975. doi:10.1002/cncr.29440
    OpenUrlCrossRef
  182. 182.
    Shelke, A. R., Roscoe, J. A., Morrow, G. R., Colman, L. K., Banerjee, T. K., & Kirshner JJ. 基因的改变NIH Public Access. Bone. 2008;23(1):1–7. doi:10.1038/jid.2014.371
    OpenUrlCrossRef
  183. 183.↵
    Shepshelovich D, Xu W, Lu L, et al. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. J Thorac Oncol. 2019. doi:10.1016/j.jtho.2019.05.031
    OpenUrlCrossRef
  184. 184.
    Silventoinen K, Tynelius P, Rasmussen F. Weight status in young adulthood and survival after cardiovascular diseases and cancer. Int J Epidemiol. 2014;43(4):11971204. doi:10.1093/ije/dyu091
    OpenUrlCrossRefPubMed
  185. 185.
    Sinicrope FA, Foster NR, Yoon HH, et al. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012;30(4):406–412. doi:10.1200/JCO.2011.39.2563
    OpenUrlAbstract/FREE Full Text
  186. 186.
    Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR. Association of Obesity With Tumor Characteristics and Treatment Failure of Prostate Cancer in African-American and European American Men. J Urol. 2007;178(5):19391945. doi:10.1016/j.juro.2007.07.021
    OpenUrlCrossRef
  187. 187.
    Sparano JA, Wang M, Zhao F, et al. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst. 2012;104(5):406–414. doi:10.1093/jnci/djr543
    OpenUrlCrossRefPubMedWeb of Science
  188. 188.
    Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012;118(23):5937–5946. doi:10.1002/cncr.27527
    OpenUrlCrossRefPubMed
  189. 189.
    Spiess PE, Kurian T, Lin HY, et al. Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy. BJU Int. 2012;110(11 B). doi:10.1111/j.1464410X.2012.11155.x
    OpenUrlCrossRef
  190. 190.↵
    Spreafico A, Coate L, Zhai R, et al. Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. Cancer Epidemiol. 2017;47:28–34. doi:10.1016/j.canep.2016.11.009
    OpenUrlCrossRef
  191. 191.↵
    Su HI, Sue LY, Flatt SW, Natarajan L, Patterson RE, Pierce JP. Endogenous estradiol is not associated with poor physical health in postmenopausal breast cancer survivors. J Women’s Heal. 2013;22(12):1043–1048. doi:10.1089/jwh.2013.4375
    OpenUrlCrossRef
  192. 192.
    Sun L, Zhu Y, Qian Q, Tang L. Body mass index and prognosis of breast cancer. Med (United States). 2018;97(26). doi:10.1097/MD.0000000000011220
    OpenUrlCrossRef
  193. 193.
    Sun X, Nichols HB, Robinson W, Sherman ME, Olshan AF, Troester MA. Post-diagnosis adiposity and survival among breast cancer patients: influence of breast cancer subtype. Cancer Causes Control. 2015;26(12):1803–1811. doi:10.1007/s10552-015-0673-6
    OpenUrlCrossRef
  194. 194.
    Sundelöf M, Lagergren J, Ye W. Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. Eur J Cancer. 2008;44(11):1566–1571. doi:10.1016/j.ejca.2008.04.002
    OpenUrlCrossRefPubMedWeb of Science
  195. 195.
    Taghizadeh N, Boezen HM, Schouten JP, Schröder CP, De Vries EGE, Vonk JM. BMI and lifetime changes in BMI and cancer mortality risk. PLoS One. 2015;10(4):1–16. doi:10.1371/journal.pone.0125261
    OpenUrlCrossRefPubMed
  196. 196.
    Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat. 2014;146(1):189–197. doi:10.1007/s10549-014-3002-y
    OpenUrlCrossRefPubMed
  197. 197.
    Thrift AP, Nagle CM, Fahey PP, Smithers BM, Watson DI, Whiteman DC. Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. Cancer Causes Control. 2012;23(4):555–564. doi:10.1007/s10552-012-9913-1
    OpenUrlCrossRefPubMedWeb of Science
  198. 198.
    Todo Y, Okamoto K, Minobe S, Kato H. Clinical significance of surgical staging for obese women with endometrial cancer: a retrospective analysis in a Japanese cohort. Jpn J Clin Oncol. 2014;44(10):903–909. doi:10.1093/jjco/hyu106
    OpenUrlCrossRefPubMed
  199. 199.
    Trial EI, Sorbye H, Mauer M, et al. Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients. 2012;255(3). doi:10.1097/SLA.0b013e3182456aa2
    OpenUrlCrossRefPubMed
  200. 200.↵
    Trivers KF, De Roos AJ, Gammon MD, et al. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol. 2005;3(3):225–230. doi:10.1016/S1542-3565(04)00613-5
    OpenUrlCrossRefPubMedWeb of Science
  201. 201.↵
    Tsai S, Choti MA, Assumpcao L, et al. Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: A large single-institution study. J Gastrointest Surg. 2010;14(7):1143–1150. doi:10.1007/s11605-010-1201-3
    OpenUrlCrossRefPubMed
  202. 202.
    Tseng CH. Factors associated with cancer-and non-cancer-related deaths among Taiwanese patients with diabetes after 17 years of follow-up. PLoS One. 2016;11(12):1–16. doi:10.1371/journal.pone.0147916
    OpenUrlCrossRefPubMed
  203. 203.
    Turner MC, Krewski D, Pope CA, Chen Y, Gapstur SM, Thun MJ. Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. Am J Respir Crit Care Med. 2011;184(12):1374–1381. doi:10.1164/rccm.201106-1011OC
    OpenUrlCrossRefPubMedWeb of Science
  204. 204.
    Tyler CP, Whiteman MK, Zapata LB, et al. The effect of body mass index and weight change on epithelial ovarian cancer survival in younger women: A long-term follow-up study. J Women’s Heal. 2012;21(8):865–871. doi:10.1089/jwh.2012.3487
    OpenUrlCrossRef
  205. 205.
    Valentijn TM, Galal W, Hoeks SE, Van Gestel YR, Verhagen HJ, Stolker RJ. Impact of obesity on postoperative and long-term outcomes in a general surgery population: A retrospective cohort study. World J Surg. 2013;37(11):2561–2568. doi:10.1007/s00268-013-2162-y
    OpenUrlCrossRefPubMed
  206. 206.
    Vidal AC, Howard LE, Sun SX, et al. Obesity and prostate cancer-specific mortality after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Prostate Cancer Prostatic Dis. 2017;20(1):72–78. doi:10.1038/pcan.2016.47
    OpenUrlCrossRef
  207. 207.
    Vidal AC, Howard LE, de Hoedt A, et al. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018;122(1):76–82. doi:10.1111/bju.14193
    OpenUrlCrossRef
  208. 208.
    Wang N, Khankari NK, Cai H, et al. Prediagnosis body mass index and waist–hip circumference ratio in association with colorectal cancer survival. Int J Cancer. 2017;140(2):292–301. doi:10.1002/ijc.30459
    OpenUrlCrossRef
  209. 209.
    Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141–151.doi:10.1038/s41591-018-0221-5
    OpenUrlCrossRefPubMed
  210. 210.↵
    Warren LEG, Ligibel JA, Chen YH, Truong L, Catalano PJ, Bellon JR. Body Mass Index and Locoregional Recurrence in Women with Early-Stage Breast Cancer. Ann Surg Oncol. 2016;23(12):3870–3879. doi:10.1245/s10434-016-5437-3
    OpenUrlCrossRef
  211. 211.↵
    Widschwendter P, Friedl TWP, Schwentner L, et al. The influence of obesity on survival in early, high-risk breast cancer: Results from the randomized SUCCESS A trial. Breast Cancer Res. 2015;17(1):1–11. doi:10.1186/s13058-015-0639-3
    OpenUrlCrossRefPubMed
  212. 212.
    Wu W, Liu X, Chaftari P, et al. Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: A retrospective review. PLoS One. 2015;10(3):1–17. doi:10.1371/journal.pone.0122047
    OpenUrlCrossRefPubMed
  213. 213.
    Xiao Y, Zhang S, Hou G, Zhang X, Hao X, Zhang J. Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer. Tumor Biol. 2014;35(3):2035–2045. doi:10.1007/s13277-013-1270-5
    OpenUrlCrossRefPubMed
  214. 214.
    Xu H, Cupples LA, Stokes A, Liu CT. Association of Obesity With Mortality Over 24 Years of Weight History: Findings From the Framingham Heart Study. JAMA Netw open. 2018;1(7):e184587. doi:10.1001/jamanetworkopen.2018.4587
    OpenUrlCrossRef
  215. 215.
    Xu H, Tan P, Zheng X, et al. Metabolic syndrome and upper tract urothelial carcinoma: A retrospective analysis from a large Chinese cohort. Urol Oncol Semin Orig Investig. 2019;37(4):291.e19–291.e28. doi:10.1016/j.urolonc.2018.12.005
    OpenUrlCrossRef
  216. 216.
    Yang L, Klint Å, Lambe M, et al. Predictors of ovarian cancer survival: A population-based prospective study in Sweden. Int J Cancer. 2008;123(3):672–679. doi:10.1002/ijc.23429
    OpenUrlCrossRefPubMedWeb of Science
  217. 217.
    Yang T, Liu K, Liu CF, et al. Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. Br J Surg. 2019;106(9):1228–1236. doi:10.1002/bjs.11231
    OpenUrlCrossRef
  218. 218.
    Yano Y, Kario K, Ishikawa S, et al. Associations between diabetes, leanness, and the risk of death in the japanese general population: The Jichi medical school cohort study. Diabetes Care. 2013;36(5):1186–1192. doi:10.2337/dc12-1736
    OpenUrlAbstract/FREE Full Text
  219. 219.
    Yoon HH, Lewis MA, Shi Q, et al. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol. 2011;29(34):4561–4567. doi:10.1200/JCO.2011.37.1260
    OpenUrlAbstract/FREE Full Text
  220. 220.↵
    Yoon LS, Goodman MT, Rimel BJ, Jeon CY. Statin use and survival in elderly patients with endometrial cancer. Gynecol Oncol. 2015;137(2):252–257. doi:10.1016/j.ygyno.2015.01.549
    OpenUrlCrossRef
  221. 221.↵
    You J, Huang S, Huang GQ, et al. Nonalcoholic fatty liver disease: A negative risk factor for colorectal cancer prognosis. Med (United States). 2015;94(5):e479. doi:10.1097/MD.0000000000000479
    OpenUrlCrossRef
  222. 222.↵
    Yuan C, Bao Y, Wu C, et al. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013. doi:10.1200/JCO.2013.51.7532
    OpenUrlAbstract/FREE Full Text
  223. 223.↵
    Zheng J, Li Y, Zhu S, et al. NDRG4 stratifies the prognostic value of body mass index in colorectal cancer. Oncotarget. 2016;7(2):1311–1322. doi:10.18632/oncotarget.6182
    OpenUrlCrossRef
  224. 224.↵
    Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003. doi:10.1093/jnci/djg022
    OpenUrlCrossRefPubMedWeb of Science
  225. 225.↵
    Campbell KL, Foster-Schubert KE, Alfano CM, et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: Randomized controlled trial. J Clin Oncol. 2012. doi:10.1200/JCO.2011.37.9792
    OpenUrlAbstract/FREE Full Text
  226. 226.↵
    Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel A V., Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: The cancer prevention study-II nutrition cohort. J Clin Oncol. 2012. doi:10.1200/JCO.2011.38.0287
    OpenUrlAbstract/FREE Full Text
  227. 227.↵
    Renehan AG, Roberts DL, Dive C. Obesity and cancer: Pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008. doi:10.1080/13813450801954303
    OpenUrlCrossRefPubMed
  228. 228.↵
    Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA - J Am Med Assoc. 2009. doi:10.1001/jama.2008.864
    OpenUrlCrossRefPubMedWeb of Science
  229. 229.↵
    Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol. 2012. doi:10.1093/annonc/mdr603
    OpenUrlCrossRefPubMedWeb of Science
  230. 230.↵
    Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer. 2014. doi:10.1038/nrc3829
    OpenUrlCrossRefPubMed
  231. 231.↵
    Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002. doi:10.1038/sj.bjc.6600466
    OpenUrlCrossRefPubMedWeb of Science
  232. 232.↵
    Patel JD, Pereira JR, Chen J, et al. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol. 2016. doi:10.1093/annonc/mdw211
    OpenUrlCrossRefPubMed
  233. 233.
    Naik GS, Waikar SS, Johnson AEW, et al. Complex inter-relationship of body mass index, gender and serum creatinine on survival: Exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019. doi:10.1186/s40425-019-0512-5
    OpenUrlAbstract/FREE Full Text
  234. 234.
    Richtig G, Hoeller C, Wolf M, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study. PLoS One. 2018. doi:10.1371/journal.pone.0204729
    OpenUrlCrossRef
  235. 235.
    Santoni M, Cortellini A, Buti S. Unlocking the secret of the obesity paradox in renal tumours. Lancet Oncol. 2020. doi:10.1016/S1470-2045(19)30783-1
    OpenUrlCrossRef
  236. 236.
    Sanchez A, Furberg H, Kuo F, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol. 2020. doi:10.1016/S1470-2045(19)30797-1
    OpenUrlCrossRef
  237. 237.
    Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, et al. White Adipose Tissue Is a Reservoir for Memory T Cells and Promotes Protective Memory Responses to Infection. Immunity. 2017. doi:10.1016/j.immuni.2017.11.009
    OpenUrlCrossRefPubMed
  238. 238.
    Tucker JM, Tucker LA, Lecheminant J, Bailey B. Obesity increases risk of declining physical activity over time in women: A prospective cohort study. Obesity. 2013. doi:10.1002/oby.20415
    OpenUrlCrossRef
  239. 239.
    Pietiläinen KH, Kaprio J, Borg P, et al. Physical inactivity and obesity: A vicious circle. Obesity. 2008. doi:10.1038/oby.2007.72
    OpenUrlCrossRefPubMed
  240. 240.↵
    Spei ME, Samoli E, Bravi F, La Vecchia C, Bamia C, Benetou V. Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and breast cancer survival. Breast. 2019. doi:10.1016/j.breast.2019.02.001
    OpenUrlCrossRef
  241. 241.↵
    Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity and mortality in colorectal cancer: A meta-Analysis of prospective cohort studies. Int J Cancer. 2013. doi:10.1002/ijc.28208
    OpenUrlCrossRefPubMedWeb of Science
  242. 242.↵
    MacMahon S, Baigent C, Duffy S, et al. Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. Lancet. 2009. doi:10.1016/S0140-6736(09)60318-4
    OpenUrlCrossRefPubMedWeb of Science
  243. 243.↵
    Renehan AG, Harvie M, Cutress RI, et al. How to manage the obese patient with cancer. J Clin Oncol. 2016. doi:10.1200/JCO.2016.69.1899
    OpenUrlCrossRef
  244. 244.↵
    Hourdequin KC, Schpero WL, McKenna DR, Piazik BL, Larson RJ. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: A systematic review and meta-analysis. Ann Oncol. 2013. doi:10.1093/annonc/mdt294
    OpenUrlCrossRefPubMed
Back to top
Posted May 02, 2020.
Download PDF
Data/Code
Email
Obesity paradox in patients with cancer: A systematic review and meta-analysis of 6,320,365 patients
Fausto Petrelli, Alessio Cortellini, Alice Indini, Gianluca Tomasello, Michele Ghidini, Olga Nigro, Massimiliano Salati, Lorenzo Dottorini, Alessandro Iaculli, Antonio Varricchio, Valentina Rampulla, Sandro Barni, Mary Cabiddu, Antonio Bossi, Antonio Ghidini, Alberto Zaniboni
medRxiv 2020.04.28.20082800; doi: https://doi.org/10.1101/2020.04.28.20082800
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area